The Endocrinology Reimbursement Landscape
The specialty is paid for procedures it doesn't do — and underpaid for the thinking it does.
Endocrinology's core product is cognitive: complex, longitudinal management of diabetes, thyroid, osteoporosis, and pituitary and adrenal disease. Yet the margin that goes uncaptured lives in the recurring programs the panel already qualifies for.
The physician fee schedule rewards procedural intensity, and endocrinology has little of it. Office E/M visits anchor the P&L, but they carry a low RVU-per-visit relative to the time and clinical complexity each encounter demands, and the Medicare conversion factor erodes in real terms every year with no automatic inflation update. The result is a specialty whose intellectual work is structurally undervalued at the visit level.
The offsets are real but under-billed. Continuous glucose monitor interpretation, remote patient monitoring, and chronic care management convert an existing diabetes panel into recurring, high-margin revenue; thyroid ultrasound and fine-needle-aspiration biopsy add a modest but defensible ancillary stream. Meanwhile GLP-1 demand, aggressive prior authorization and step therapy on diabetes drugs and devices, a national endocrinologist shortage, and emerging value-based diabetes and obesity arrangements are all reshaping the economics at once — and the same panel can be worth dramatically more depending on how it is coded, contracted, and risk-managed. That is precisely where Fulcrum works.
Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.
